SPPI Related Analyst Comments
-
Needham & Company Maintains a 'Buy' on Sagent Pharmaceuticals (SGNT); Getting Some Mojo Back
-
Auriga Reiterates a 'Buy' on Spectrum Pharmaceuticals (SPPI); Generic Leucovorin Shortage Continues
-
Auriga Reiterates a 'Buy' on Spectrum Pharmaceuticals (SPPI); February Demand for Fusilev Hits Record
-
Canaccord Genuity Maintains a 'Buy' on Spectrum Pharmaceuticals (SPPI); Mixed Q4 Results
-
Auriga Reiterates a 'Buy' on Spectrum Pharmaceuticals (SPPI); Share Price Decline Unwarranted; Fundamentals Remain Strong
-
Short Interest Ticks Up in Large-Cap Biotech, Specifically Amgen (AMGN)
-
Morgan Joseph Reiterates a 'Buy' on Spectrum Pharmaceuticals (SPPI); Attractive Valuation
-
Morgan Joseph Raises Price Target on Spectrum Pharmaceuticals (SPPI) Following FDA Approval of Fusilev for Colorectal Cancer
-
Morgan Joseph Adds Onyx Pharma (ONXX) to 'Trading List' Following Positive Data on Carfilzomib
-
Morgan Joseph Reiterates a 'Buy' on Spectrum Pharmaceuticals (SPPI); Zevalin Sales Trends Encouraging
-
Morgan Joseph Adds Spectrum Pharmaceuticals (SPPI) to Trading List; Expect Strong Growth From Zevalin
-
Rodman & Renshaw Pounds Table on Spectrum Pharma (SPPI) Following Positive Trial Data
-
Rodman & Renshaw Said SPPI's Interim Phase 3 Results Should Increase Shareholder Value
-
Rodman & Renshaw Reiterates Outperform Rating on SPPI
Back to SPPI Stock Lookup
